Vanda, Biotoscana in deal for schizophrenia drug Fanapt in Argentina
This article was originally published in Scrip
Executive Summary
Vanda Pharmaceuticals, the Rockville, Maryland-based developer of products for CNS disorders, has entered into an exclusive licence agreement with Biotoscana Farma, a wholly owned subsidiary of Biotoscana International, for the commercialisation of the twice-daily, oral atypical antipsychotic Fanapt (iloperidone) in Argentina.